製品番号: HY-B0402

Amantadine

(別名: 1-Adamantanamine; 1-Aminoadamantane; 1-アダマンタナミン)

11 Cited Publications

カスタマーレビュー

Based on 11 publication(s) in Google Scholar

Amantadine (1-Adamantanamine) is an orally avtive and potent antiviral agent with activity against influenza A viruses. Amantadine inhibits several ion channels such as NMDA and M2, and also inhibits Coronavirus ion channels. Amantadine also has anti-orthopoxvirus and anticancer activity. Amantadine can be used for Parkinson's disease, postoperative cognitive dysfunction (POCD) and COVID-19 research.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.90%
CAS 番号: 768-94-5
分子式: C₁₀H₁₇N
分子量:151.25

保管条件:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Amantadine 構造式

CAS 番号: 768-94-5

容量

価格（税別）

在庫状況

数量

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

お問い合わせ Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability お問い合わせ Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

バルクお問い合わせ

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- Cellular Effect
- 体外実験
- 体内実験
化学情報
Publications (11)
溶剤 & 溶解度
- 体外
- 体内
純度とドキュメンテーション
参考文献
Help & FAQs
Bioz

生物活性

製品説明

IC₅₀ & Target

CDK2

Bcl-2

Bax

CDK アイソフォーム固有の製品をすべて表示 :

Bcl-2 Family アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
HEK293	IC₅₀	1.6 μM Compound: 1	Blockade of Influenza A virus (A/England/195/2009(H1N1)) full length M2 proton channel expressed in HEK cells after 3 mins by voltage clamp technique Blockade of Influenza A virus (A/England/195/2009(H1N1)) full length M2 proton channel expressed in HEK cells after 3 mins by voltage clamp technique	[PMID: 24793875]
HEK293	IC₅₀	3.525 μM Compound: 1	Inhibition of avian influenza virus H5N1 matrix 2 protein expressed in HEK293 cells assessed as cell viability after 24 hrs Inhibition of avian influenza virus H5N1 matrix 2 protein expressed in HEK293 cells assessed as cell viability after 24 hrs	[PMID: 20394375]
HEK293	IC₅₀	37.8 μM Compound: amantadine	Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	[PMID: 23241029]
HEK293	IC₅₀	8.8 μM Compound: 1	Inhibition of avian influenza virus (H5N1) matrix 2 protein expressed in HEK293 cells by path clamp electrophysiology method Inhibition of avian influenza virus (H5N1) matrix 2 protein expressed in HEK293 cells by path clamp electrophysiology method	[PMID: 20394375]
MDCK	CC₅₀	>100 μM Compound: 1	Cytotoxicity against MDCK cells measured after 72 hrs et staining-based microscopic analysis Cytotoxicity against MDCK cells measured after 72 hrs et staining-based microscopic analysis	[PMID: 28107633]
MDCK	CC₅₀	>100 μM Compound: 1	Cytotoxicity against MDCK cells after 72 hrs by crystal violet staining based spectrophotometric method Cytotoxicity against MDCK cells after 72 hrs by crystal violet staining based spectrophotometric method	[PMID: 29541360]
MDCK	CC₅₀	>100 μM Compound: amantadin	Cytotoxicity against MDCK cells assessed as decrease in cell viability by MTS assay Cytotoxicity against MDCK cells assessed as decrease in cell viability by MTS assay	[PMID: 18778942]
MDCK	CC₅₀	>100 μM Compound: amantadine	Cytotoxicity against dog MDCK cells assessed as cell viability after 72 hrs by MTS assay Cytotoxicity against dog MDCK cells assessed as cell viability after 72 hrs by MTS assay	[PMID: 24900429]
MDCK	CC₅₀	>100 μM Compound: Amantadine	Cytotoxicity against MDCK cells after 40 hrs by Celltiter-Glo assay Cytotoxicity against MDCK cells after 40 hrs by Celltiter-Glo assay	[PMID: 26686929]
MDCK	CC₅₀	>100 μM Compound: Amantadine	Cytotoxicity against dog MDCK cells assessed as reduction in cell viability incubated for 3 days by coulter counter method Cytotoxicity against dog MDCK cells assessed as reduction in cell viability incubated for 3 days by coulter counter method	[PMID: 31586832]
MDCK	CC₅₀	>100 μM Compound: AMD	Cytotoxicity against MDCK cells after 3 days by CCK-8 assay Cytotoxicity against MDCK cells after 3 days by CCK-8 assay	[PMID: 22332894]
MDCK	CC₅₀	>100 μM Compound: AMD	Cytotoxicity against MDCK cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against MDCK cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 31559005]
MDCK	CC₅₀	>100 μM Compound: AMN	Cytotoxicity against MDCK cells by MTS assay Cytotoxicity against MDCK cells by MTS assay	[PMID: 19281225]
MDCK	CC₅₀	>100 μM Compound: AMT	Cytotoxicity against MDCK cells after 3 days by fluorescein diacetate-based fluorimetric analysis Cytotoxicity against MDCK cells after 3 days by fluorescein diacetate-based fluorimetric analysis	[PMID: 23419738]
MDCK	CC₅₀	>100 μM Compound: AMT	Cytotoxicity against MDCK cells assessed as reduction in cell viability measured for 48 hrs by MTT assay Cytotoxicity against MDCK cells assessed as reduction in cell viability measured for 48 hrs by MTT assay	[PMID: 36764470]
MDCK	CC₅₀	>1000 μg/mL Compound: Amantadin	Cytotoxicity against MDCK cells by MTS assay Cytotoxicity against MDCK cells by MTS assay	[PMID: 20724039]
MDCK	CC₅₀	>200 μg/mL Compound: Amantadine	Cytotoxicity against MDCK cells assessed as cell viability by MTS assay Cytotoxicity against MDCK cells assessed as cell viability by MTS assay	[PMID: 20971531]
MDCK	CC₅₀	>200 μM Compound: Amantadine	Cytotoxicity against MDCK cells assessed as cell viability by colorimetric formazan-based MTS assay Cytotoxicity against MDCK cells assessed as cell viability by colorimetric formazan-based MTS assay	[PMID: 22459876]
MDCK	CC₅₀	>200 μM Compound: amantadine	Cytotoxicity against MDCK cells assessed as cell growth after 40 hrs by CellTiter-Glo assay Cytotoxicity against MDCK cells assessed as cell growth after 40 hrs by CellTiter-Glo assay	[PMID: 25681711]
MDCK	CC₅₀	>200 μM Compound: Amantadine	Cytotoxicity against MDCK cells assessed as cell viability measured after 4 days by formazan-based MTS assay Cytotoxicity against MDCK cells assessed as cell viability measured after 4 days by formazan-based MTS assay	[PMID: 27112451]
MDCK	CC₅₀	>200 μM Compound: Amantadine	Cytotoxicity against MDCK cells assessed as reduction in cell viability after 4 days by MTS assay Cytotoxicity against MDCK cells assessed as reduction in cell viability after 4 days by MTS assay	[PMID: 31753804]
MDCK	CC₅₀	>220.36 μM Compound: 1-Adamantylamine	Cytotoxicity against MDCK cells by MTT assay Cytotoxicity against MDCK cells by MTT assay	[PMID: 22226654]
MDCK	CC₅₀	>220.36 μM Compound: 1-Adamantylamine	Cytotoxicity against MDCK cells by MTT assay Cytotoxicity against MDCK cells by MTT assay	[PMID: 23538114]
MDCK	CC₅₀	>400 μM Compound: Amantadine	Cytotoxicity against dog MDCK cells assessed as reduction in cell viability measured after 5 to 6 days by MTS assay Cytotoxicity against dog MDCK cells assessed as reduction in cell viability measured after 5 to 6 days by MTS assay	[PMID: 28477572]
MDCK	CC₅₀	>440.99 μM Compound: AMD	Cytotoxicity against MDCK cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against MDCK cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 30292897]
MDCK	CC₅₀	>500 μM Compound: Amantadine	Cytotoxicity against dog MDCK cells assessed as cell viability by MTS assay Cytotoxicity against dog MDCK cells assessed as cell viability by MTS assay	[PMID: 23117173]
MDCK	CC₅₀	>500 μM Compound: Amantadine	Cytotoxicity against MDCK cells assessed as reduction in cell viability after 72 hrs by MTS assay Cytotoxicity against MDCK cells assessed as reduction in cell viability after 72 hrs by MTS assay	[PMID: 24974341]
MDCK	CC₅₀	>500 μM Compound: Amantadine	Cytotoxicity against MDCK cells after 72 hrs by MTS assay Cytotoxicity against MDCK cells after 72 hrs by MTS assay	[PMID: 25752526]
MDCK	CC₅₀	>500 μM Compound: Amantadine	Cytotoxicity against MDCK cells assessed as reduction in cell viability after 72 hrs by MTS assay Cytotoxicity against MDCK cells assessed as reduction in cell viability after 72 hrs by MTS assay	[PMID: 28418242]
MDCK	CC₅₀	>500 μM Compound: Amantadine	Cytotoxicity against MDCK cells assessed as decrease in cell viability after 72 hrs by MTS assay Cytotoxicity against MDCK cells assessed as decrease in cell viability after 72 hrs by MTS assay	[PMID: 29220568]
MDCK	CC₅₀	>500 μM Compound: Amantadine	Cytotoxicity against MDCK cells assessed as reduction in cell viability measured after 3 to 6 days by MTS assay Cytotoxicity against MDCK cells assessed as reduction in cell viability measured after 3 to 6 days by MTS assay	[PMID: 29886325]
MDCK	CC₅₀	>500 μM Compound: Amantadine	Cytotoxicity against MDCK cells assessed as reduction in cell viability after 3 days by MTS assay Cytotoxicity against MDCK cells assessed as reduction in cell viability after 3 days by MTS assay	[PMID: 30170320]
MDCK	CC₅₀	>500 μM Compound: Amt	Cytotoxicity against MDCK cells after 72 hrs by MTS assay Cytotoxicity against MDCK cells after 72 hrs by MTS assay	[PMID: 21466220]
MDCK	CC₅₀	>500 μM Compound: Amt	Cytotoxicity against MDCK cells after 72 hrs by MTS assay Cytotoxicity against MDCK cells after 72 hrs by MTS assay	[PMID: 24237039]
MDCK	CC₅₀	>500 μM Compound: Amt	Cytotoxicity against MDCK cells assessed as cell viability after 72 hrs by MTS assay Cytotoxicity against MDCK cells assessed as cell viability after 72 hrs by MTS assay	[PMID: 24941437]
MDCK	CC₅₀	>80 μM Compound: Amantadine	Cytotoxicity against MDCK cells assessed as reduction in cell viability after 48 hrs by CellTiter-Glo assay Cytotoxicity against MDCK cells assessed as reduction in cell viability after 48 hrs by CellTiter-Glo assay	[PMID: 25147619]
MDCK	CC₅₀	218.92 μM Compound: Amantadine	Cytotoxicity against MDCK cells after 72 hrs by MTT assay Cytotoxicity against MDCK cells after 72 hrs by MTT assay	[PMID: 24803363]
MDCK	CC₅₀	284 μM Compound: Amantadine	Cytotoxicity against MDCK cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against MDCK cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 30746065]
MDCK	CC₅₀	284.1 μM Compound: Amantadine	Cytotoxicity against MDCK cells after 48 hrs by MTT assay Cytotoxicity against MDCK cells after 48 hrs by MTT assay	[PMID: 30108810]
MDCK	EC₅₀	>10 μM Compound: amantadine	Antiviral activity against Influenza A virus A/California/07/2009 infected in MDCK cells assessed as cell protection after 3 days by cytopathic effect assay Antiviral activity against Influenza A virus A/California/07/2009 infected in MDCK cells assessed as cell protection after 3 days by cytopathic effect assay	[PMID: 25019388]
MDCK	EC₅₀	>10 μM Compound: amantadine	Antiviral activity against Influenza A virus A/Georgia/20/2006 infected in MDCK cells assessed as cell protection after 3 days by cytopathic effect assay Antiviral activity against Influenza A virus A/Georgia/20/2006 infected in MDCK cells assessed as cell protection after 3 days by cytopathic effect assay	[PMID: 25019388]
MDCK	EC₅₀	>10 μM Compound: amantadine	Antiviral activity against Influenza A virus A/Mexico/4108/2009 infected in MDCK cells assessed as cell protection after 3 days by cytopathic effect assay Antiviral activity against Influenza A virus A/Mexico/4108/2009 infected in MDCK cells assessed as cell protection after 3 days by cytopathic effect assay	[PMID: 25019388]
MDCK	EC₅₀	>10 μM Compound: amantadine	Antiviral activity against Influenza A virus A/New York/18/2009 infected in MDCK cells assessed as cell protection after 3 days by cytopathic effect assay Antiviral activity against Influenza A virus A/New York/18/2009 infected in MDCK cells assessed as cell protection after 3 days by cytopathic effect assay	[PMID: 25019388]
MDCK	EC₅₀	>10 μM Compound: amantadine	Antiviral activity against Influenza A virus A/Puerto Rico/8/34 infected in MDCK cells assessed as cell protection after 3 days by cytopathic effect assay Antiviral activity against Influenza A virus A/Puerto Rico/8/34 infected in MDCK cells assessed as cell protection after 3 days by cytopathic effect assay	[PMID: 25019388]
MDCK	EC₅₀	>10 μM Compound: amantadine	Antiviral activity against Influenza A virus A/Texas/48/2009 infected in MDCK cells assessed as cell protection after 3 days by cytopathic effect assay Antiviral activity against Influenza A virus A/Texas/48/2009 infected in MDCK cells assessed as cell protection after 3 days by cytopathic effect assay	[PMID: 25019388]
MDCK	EC₅₀	>100 μM Compound: amantadine	Antiviral activity against amantidine and rimantadine-resistant Influenza B virus (B/HK/5/72) infected in MDCK cells assessed as virus-induced cytopathic effect by MTS assay Antiviral activity against amantidine and rimantadine-resistant Influenza B virus (B/HK/5/72) infected in MDCK cells assessed as virus-induced cytopathic effect by MTS assay	[PMID: 24900429]
MDCK	EC₅₀	>100 μM Compound: amantadine	Antiviral activity against amantidine and rimantadine-resistant Influenza B virus (B/HK/5/72) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis Antiviral activity against amantidine and rimantadine-resistant Influenza B virus (B/HK/5/72) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis	[PMID: 24900429]
MDCK	EC₅₀	>100 μM Compound: AMN	Antiviral activity against influenza B virus in MDCK cells assessed as reduction of virus-induced cytopathicity by MTS method Antiviral activity against influenza B virus in MDCK cells assessed as reduction of virus-induced cytopathicity by MTS method	[PMID: 19281225]
MDCK	EC₅₀	>100 μM Compound: AMN	Antiviral activity against influenza B virus in MDCK cells assessed as reduction of virus-induced cytopathicity by visual cytopathic effect scoring method Antiviral activity against influenza B virus in MDCK cells assessed as reduction of virus-induced cytopathicity by visual cytopathic effect scoring method	[PMID: 19281225]
MDCK	EC₅₀	>100 μM Compound: AMN	Antiviral activity against influenza H1N1 virus in MDCK cells assessed as reduction of virus-induced cytopathicity by MTS method Antiviral activity against influenza H1N1 virus in MDCK cells assessed as reduction of virus-induced cytopathicity by MTS method	[PMID: 19281225]
MDCK	EC₅₀	>100 μM Compound: AMN	Antiviral activity against influenza H1N1 virus in MDCK cells assessed as reduction of virus-induced cytopathicity by visual cytopathic effect scoring method Antiviral activity against influenza H1N1 virus in MDCK cells assessed as reduction of virus-induced cytopathicity by visual cytopathic effect scoring method	[PMID: 19281225]
MDCK	EC₅₀	>100 μM Compound: AMT	Antiviral activity against Influenza B virus (B/Brisbane/60/2008) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis Antiviral activity against Influenza B virus (B/Brisbane/60/2008) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis	[PMID: 23419738]
MDCK	EC₅₀	>100 μM Compound: AMT	Antiviral activity against Influenza B virus (B/Lee/40) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis Antiviral activity against Influenza B virus (B/Lee/40) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis	[PMID: 23419738]
MDCK	EC₅₀	>100 μM Compound: AMT	Antiviral activity against Influenza B virus (B/Panama/45/1990) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis Antiviral activity against Influenza B virus (B/Panama/45/1990) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis	[PMID: 23419738]
MDCK	EC₅₀	>100 μM Compound: AMT	Antiviral activity against Influenza B virus (B/Taiwan/2/62) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis Antiviral activity against Influenza B virus (B/Taiwan/2/62) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis	[PMID: 23419738]
MDCK	EC₅₀	>20 μM Compound: Amantadine	Antiviral activity against oseltamivir/amantadine-resistant Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in MDCK cells assessed as protection against virus-induced cytocidal effect after 48 hrs by CellTiter-Glo assay Antiviral activity against oseltamivir/amantadine-resistant Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in MDCK cells assessed as protection against virus-induced cytocidal effect after 48 hrs by CellTiter-Glo assay	[PMID: 25815159]
MDCK	EC₅₀	>20.51 μM Compound: Amantadine	Antiviral activity against amantadine-resistant influenza A virus HN/1222 (H3N2) infected in dog MDCK cells assessed as inhibition of virus induced cytopathic effect after 40 hrs by Cell-Titer-Glo assay Antiviral activity against amantadine-resistant influenza A virus HN/1222 (H3N2) infected in dog MDCK cells assessed as inhibition of virus induced cytopathic effect after 40 hrs by Cell-Titer-Glo assay	[PMID: 26686929]
MDCK	EC₅₀	>200 μg/mL Compound: Amantadine	Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay	[PMID: 20971531]
MDCK	EC₅₀	>200 μg/mL Compound: Amantadine	Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE	[PMID: 20971531]
MDCK	EC₅₀	>200 μM Compound: Amantadine	Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by colorimetric formazan-based MTS assay Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by colorimetric formazan-based MTS assay	[PMID: 22459876]
MDCK	EC₅₀	>200 μM Compound: Amantadine	Antiviral activity against Influenza B virus infected in MDCK cells assessed as reduction visual scoring of virus-induced cytopathogenicity after 4 days Antiviral activity against Influenza B virus infected in MDCK cells assessed as reduction visual scoring of virus-induced cytopathogenicity after 4 days	[PMID: 22459876]
MDCK	EC₅₀	>200 μM Compound: amantadine	Antiviral activity against influenza B virus infected in dog MDCK cells assessed as reduction of virus-induced cytopathogenicity by MTS assay Antiviral activity against influenza B virus infected in dog MDCK cells assessed as reduction of virus-induced cytopathogenicity by MTS assay	[PMID: 23811093]
MDCK	EC₅₀	>200 μM Compound: Amantadine	Antiviral activity against oseltamivir-resistant influenza A virus LN/1109 (H1N1) infected in dog MDCK cells assessed as inhibition of virus induced cytopathic effect after 40 hrs by Cell-Titer-Glo assay Antiviral activity against oseltamivir-resistant influenza A virus LN/1109 (H1N1) infected in dog MDCK cells assessed as inhibition of virus induced cytopathic effect after 40 hrs by Cell-Titer-Glo assay	[PMID: 26686929]
MDCK	EC₅₀	>500 μM Compound: Amantadine	Antiviral activity against Influenza B virus (B/HK/5/72) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by microscopic analysis Antiviral activity against Influenza B virus (B/HK/5/72) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by microscopic analysis	[PMID: 23117173]
MDCK	EC₅₀	>500 μM Compound: Amantadine	Antiviral activity against Influenza B virus (B/HK/5/72) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by MTS assay Antiviral activity against Influenza B virus (B/HK/5/72) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by MTS assay	[PMID: 23117173]
MDCK	EC₅₀	>500 μM Compound: Amantadine	Antiviral activity against Influenza B/HK/5/72 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect measured on day 3 post infection by MTS assay Antiviral activity against Influenza B/HK/5/72 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect measured on day 3 post infection by MTS assay	[PMID: 23149298]
MDCK	EC₅₀	>500 μM Compound: Amantadine	Antiviral activity against Influenza A virus A/Virginia/ATCC3/2009 infected in MDCK cells assessed as reduction in host cell viability after 72 hrs by MTS assay Antiviral activity against Influenza A virus A/Virginia/ATCC3/2009 infected in MDCK cells assessed as reduction in host cell viability after 72 hrs by MTS assay	[PMID: 24974341]
MDCK	EC₅₀	>500 μM Compound: Amantadine	Antiviral activity against Influenza A virus A/Virginia/ATCC3/2009 infected in MDCK cells assessed as virus-induced cytopathic effect after 72 hrs by microscopy Antiviral activity against Influenza A virus A/Virginia/ATCC3/2009 infected in MDCK cells assessed as virus-induced cytopathic effect after 72 hrs by microscopy	[PMID: 24974341]
MDCK	EC₅₀	>500 μM Compound: Amantadine	Antiviral activity against Influenza B virus (B/HK/05/1972) infected in MDCK cells assessed as reduction in host cell viability after 72 hrs by MTS assay Antiviral activity against Influenza B virus (B/HK/05/1972) infected in MDCK cells assessed as reduction in host cell viability after 72 hrs by MTS assay	[PMID: 24974341]
MDCK	EC₅₀	>500 μM Compound: Amantadine	Antiviral activity against Influenza B virus (B/HK/05/1972) infected in MDCK cells assessed as virus-induced cytopathic effect after 72 hrs by microscopy Antiviral activity against Influenza B virus (B/HK/05/1972) infected in MDCK cells assessed as virus-induced cytopathic effect after 72 hrs by microscopy	[PMID: 24974341]
MDCK	EC₅₀	>500 μM Compound: Amantadine	Antiviral activity against Influenza B virus (B/Hong Kong/05/1972) infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay Antiviral activity against Influenza B virus (B/Hong Kong/05/1972) infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay	[PMID: 25752526]
MDCK	EC₅₀	>500 μM Compound: Amantadine	Antiviral activity against Influenza B virus (B/Hong Kong/05/1972) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by microscopic analysis Antiviral activity against Influenza B virus (B/Hong Kong/05/1972) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by microscopic analysis	[PMID: 25752526]
MDCK	EC₅₀	>500 μM Compound: Amantadine	Antiviral activity against Influenza B virus infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay Antiviral activity against Influenza B virus infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay	[PMID: 32214762]
MDCK	EC₅₀	>500 μM Compound: Amt	Antiviral activity against Influenza B virus (B/Hong Kong/05/1972) harboring wild type M2 channel infected in MDCK cells assessed as reduction of cytopathic effect after 72 hrs by microsocopic analysis Antiviral activity against Influenza B virus (B/Hong Kong/05/1972) harboring wild type M2 channel infected in MDCK cells assessed as reduction of cytopathic effect after 72 hrs by microsocopic analysis	[PMID: 24237039]
MDCK	EC₅₀	>500 μM Compound: Amt	Antiviral activity against Influenza B virus (B/Hong Kong/05/1972) harboring wild type M2 channel infected in MDCK cells assessed as reduction of cytopathic effect after 72 hrs by MTS assay Antiviral activity against Influenza B virus (B/Hong Kong/05/1972) harboring wild type M2 channel infected in MDCK cells assessed as reduction of cytopathic effect after 72 hrs by MTS assay	[PMID: 24237039]
MDCK	EC₅₀	>80 μM Compound: Amantadine	Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytocidal activity after 48 hrs by CellTiter-Glo assay Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytocidal activity after 48 hrs by CellTiter-Glo assay	[PMID: 25147619]
MDCK	EC₅₀	0.04 μM Compound: Amantadine	Antiviral activity against Influenza A virus A/Puerto Rico/8/34 expressing wild type M2 proton channel infected in MDCK cells assessed as inhibition of viral replication measured after 10 hrs by miniplaque assay Antiviral activity against Influenza A virus A/Puerto Rico/8/34 expressing wild type M2 proton channel infected in MDCK cells assessed as inhibition of viral replication measured after 10 hrs by miniplaque assay	[PMID: 27187859]
MDCK	EC₅₀	0.054 μg/mL Compound: Amantadine	Antiviral activity against influenza A virus NJH1N1 in MDCK cells by hemadsorption-inhibition assay Antiviral activity against influenza A virus NJH1N1 in MDCK cells by hemadsorption-inhibition assay	[PMID: 9214738]
MDCK	EC₅₀	0.14 μM Compound: amantadine	Antiviral activity against Influenza A virus (A/HK/7/87(H3N2)) infected in MDCK cells assessed as virus plaque reduction preincubated for 1 hr followed by compound wash out and incubated for 72 hrs by crystal violet staining Antiviral activity against Influenza A virus (A/HK/7/87(H3N2)) infected in MDCK cells assessed as virus plaque reduction preincubated for 1 hr followed by compound wash out and incubated for 72 hrs by crystal violet staining	[PMID: 25899336]
MDCK	EC₅₀	0.2 μg/mL Compound: Amantadine	Antiviral activity against Influenza A H3N2 virus subtype infected in MDCK cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay Antiviral activity against Influenza A H3N2 virus subtype infected in MDCK cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay	[PMID: 20971531]
MDCK	EC₅₀	0.3 μg/mL Compound: Amantadine	Antiviral activity against Influenza A H3N2 virus subtype infected in MDCK cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE Antiviral activity against Influenza A H3N2 virus subtype infected in MDCK cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE	[PMID: 20971531]
MDCK	EC₅₀	0.3 μM Compound: 1; AMT	Antiviral activity against Influenza A virus A/udorn/72(H3N2) expressing wild type M2 proton channel infected in MDCK cells assessed as reduction in plaque formation preincubated for 30 mins followed by infection measured on day 2 post infection by naphth Antiviral activity against Influenza A virus A/udorn/72(H3N2) expressing wild type M2 proton channel infected in MDCK cells assessed as reduction in plaque formation preincubated for 30 mins followed by infection measured on day 2 post infection by naphth	[PMID: 26771709]
MDCK	EC₅₀	0.3 μM Compound: amantadine	Antiviral activity against influenza A virus H3N3 subtype infected in dog MDCK cells assessed as reduction of virus-induced cytopathogenicity by MTS assay Antiviral activity against influenza A virus H3N3 subtype infected in dog MDCK cells assessed as reduction of virus-induced cytopathogenicity by MTS assay	[PMID: 23811093]
MDCK	EC₅₀	0.34 μM Compound: 1	Antiviral activity against Influenza A virus A2/Taiwan/1/64(H2N2) infected in MDCK cells expressing wild type M2 after overnight incubation by fluorescence-based miniplaque assay Antiviral activity against Influenza A virus A2/Taiwan/1/64(H2N2) infected in MDCK cells expressing wild type M2 after overnight incubation by fluorescence-based miniplaque assay	[PMID: 24793875]
MDCK	EC₅₀	0.45 μM Compound: Amantadine	Antiviral activity against Influenza A virus (A/HK/7/1987(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect after 72 hrs by microscopy Antiviral activity against Influenza A virus (A/HK/7/1987(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect after 72 hrs by microscopy	[PMID: 24974341]
MDCK	EC₅₀	0.5 μM Compound: Amantadine	Antiviral activity against Influenza A virus (A/HK/7/1987(H3N2)) infected in MDCK cells assessed as reduction in host cell viability after 72 hrs by MTS assay Antiviral activity against Influenza A virus (A/HK/7/1987(H3N2)) infected in MDCK cells assessed as reduction in host cell viability after 72 hrs by MTS assay	[PMID: 24974341]
MDCK	EC₅₀	0.6 μM Compound: AMT	Antiviral activity against Influenza A virus (A/Taiwan/1/1986(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis Antiviral activity against Influenza A virus (A/Taiwan/1/1986(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis	[PMID: 23419738]
MDCK	EC₅₀	0.82 μM Compound: Amt	Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) harboring wild type M2 channel infected in MDCK cells assessed as reduction of cytopathic effect after 72 hrs by MTS assay Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) harboring wild type M2 channel infected in MDCK cells assessed as reduction of cytopathic effect after 72 hrs by MTS assay	[PMID: 24237039]
MDCK	EC₅₀	0.84 μM Compound: Amt	Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) harboring wild type M2 channel infected in MDCK cells assessed as reduction of cytopathic effect after 72 hrs by microsocopic analysis Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) harboring wild type M2 channel infected in MDCK cells assessed as reduction of cytopathic effect after 72 hrs by microsocopic analysis	[PMID: 24237039]
MDCK	EC₅₀	1.2 μM Compound: Amantadine	Antiviral activity against IInfluenza A virus H3N2 A/HK/7/87 infected in MDCK cells after 4 days by MTS assay Antiviral activity against IInfluenza A virus H3N2 A/HK/7/87 infected in MDCK cells after 4 days by MTS assay	[PMID: 31753804]
MDCK	EC₅₀	1.4 μM Compound: amantadine	Antiviral activity against Influenza A virus (A/HK/7/87(H3N2)) infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay Antiviral activity against Influenza A virus (A/HK/7/87(H3N2)) infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay	[PMID: 25899336]
MDCK	EC₅₀	1.4 μM Compound: amantadine	Antiviral activity against Influenza A virus (A/HK/7/87(H3N2)) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by microscopic analysis Antiviral activity against Influenza A virus (A/HK/7/87(H3N2)) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by microscopic analysis	[PMID: 25899336]
MDCK	EC₅₀	1.4 μM Compound: Amt	Antiviral activity against Influenza A virus (A/HK/7/87(H3N2)) harboring wild type M2 channel infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay Antiviral activity against Influenza A virus (A/HK/7/87(H3N2)) harboring wild type M2 channel infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay	[PMID: 24941437]
MDCK	EC₅₀	1.4 μM Compound: Amt	Antiviral activity against Influenza A virus (A/HK/7/87(H3N2)) harboring wild type M2 channel infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 72 hrs by microscopic analysis Antiviral activity against Influenza A virus (A/HK/7/87(H3N2)) harboring wild type M2 channel infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 72 hrs by microscopic analysis	[PMID: 24941437]
MDCK	EC₅₀	1.5 μM Compound: Amantadine	Antiviral activity against Influenza A virus H3N2 infected MDCK cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay Antiviral activity against Influenza A virus H3N2 infected MDCK cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay	[PMID: 32214762]
MDCK	EC₅₀	1.8 μM Compound: Amantadine	Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay	[PMID: 25752526]
MDCK	EC₅₀	1.9 μM Compound: AMT	Antiviral activity against Influenza A virus (A/Hong kong/8/1968(H2N3)) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis Antiviral activity against Influenza A virus (A/Hong kong/8/1968(H2N3)) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis	[PMID: 23419738]
MDCK	EC₅₀	1.98 μM Compound: amantadine	Antiviral activity against influenza A/Hong Kong/7/87 (H3N2) in MDCK cells assessed as inhibition of virus-induced cytopathic effect by MTS assay Antiviral activity against influenza A/Hong Kong/7/87 (H3N2) in MDCK cells assessed as inhibition of virus-induced cytopathic effect by MTS assay	[PMID: 17588747]
MDCK	EC₅₀	100 μM Compound: AMN	Antiviral activity against influenza H3N2 virus in MDCK cells assessed as reduction of virus-induced cytopathicity by visual cytopathic effect scoring method Antiviral activity against influenza H3N2 virus in MDCK cells assessed as reduction of virus-induced cytopathicity by visual cytopathic effect scoring method	[PMID: 19281225]
MDCK	EC₅₀	101 μg/mL Compound: Amantadin	Antiviral activity against influenza A virus H1N1 infected in MDCK cells assessed as protection against virus-induced cytopathogenicity after 2 days Antiviral activity against influenza A virus H1N1 infected in MDCK cells assessed as protection against virus-induced cytopathogenicity after 2 days	[PMID: 20724039]
MDCK	EC₅₀	11 μM Compound: amantadine	Antiviral activity against Influenza A virus (A/Ishikawa/7/82 (H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis Antiviral activity against Influenza A virus (A/Ishikawa/7/82 (H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis	[PMID: 24900429]
MDCK	EC₅₀	111 μM Compound: Amantadine	Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as reduction in host cell viability after 72 hrs by MTS assay Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as reduction in host cell viability after 72 hrs by MTS assay	[PMID: 24974341]
MDCK	EC₅₀	115 μg/mL Compound: Amantadin	Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as cell viability after 2 days by MTS assay Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as cell viability after 2 days by MTS assay	[PMID: 20724039]
MDCK	EC₅₀	117 μg/mL Compound: Amantadin	Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as protection against virus-induced cytopathogenicity after 2 days Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as protection against virus-induced cytopathogenicity after 2 days	[PMID: 20724039]
MDCK	EC₅₀	143.84 μM Compound: Amantadine	Antiviral activity against influenza B virus B/SZ/155 infected in dog MDCK cells assessed as inhibition of virus induced cytopathic effect after 40 hrs by Cell-Titer-Glo assay Antiviral activity against influenza B virus B/SZ/155 infected in dog MDCK cells assessed as inhibition of virus induced cytopathic effect after 40 hrs by Cell-Titer-Glo assay	[PMID: 26686929]
MDCK	EC₅₀	154 μM Compound: Amantadine	Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by colorimetric formazan-based MTS assay Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by colorimetric formazan-based MTS assay	[PMID: 22459876]
MDCK	EC₅₀	17 μM Compound: amantadine	Antiviral activity against influenza A virus H1N1 subtype infected in dog MDCK cells assessed as reduction of virus-induced cytopathogenicity by MTS assay Antiviral activity against influenza A virus H1N1 subtype infected in dog MDCK cells assessed as reduction of virus-induced cytopathogenicity by MTS assay	[PMID: 23811093]
MDCK	EC₅₀	18 μg/mL Compound: Amantadine	Antiviral activity against Influenza A H1N1 virus subtype infected in MDCK cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE Antiviral activity against Influenza A H1N1 virus subtype infected in MDCK cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE	[PMID: 20971531]
MDCK	EC₅₀	2 μM Compound: Amantadine	Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity by MTS assay Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity by MTS assay	[PMID: 20805012]
MDCK	EC₅₀	2 μM Compound: amantadine	Antiviral activity against amantadine-sensitive Influenza A virus (A/Ned/378/05 (H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis Antiviral activity against amantadine-sensitive Influenza A virus (A/Ned/378/05 (H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis	[PMID: 24900429]
MDCK	EC₅₀	2 μM Compound: Amantadine	Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by microscopic analysis Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by microscopic analysis	[PMID: 25752526]
MDCK	EC₅₀	2.3 μM Compound: Amantadine	Antiviral activity against Influenza A/HK/7/87 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect measured on day 3 post infection by MTS assay Antiviral activity against Influenza A/HK/7/87 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect measured on day 3 post infection by MTS assay	[PMID: 23149298]
MDCK	EC₅₀	2.7 μM Compound: amantadine	Antiviral activity against influenza virus A/Hong Kong/7/87 H3N2 in MDCK cells assessed as effect on virus-induced cytopathogenicity by MTS assay Antiviral activity against influenza virus A/Hong Kong/7/87 H3N2 in MDCK cells assessed as effect on virus-induced cytopathogenicity by MTS assay	[PMID: 18954995]
MDCK	EC₅₀	2.77 μM Compound: 1	Antiviral activity against Influenza A virus A/Victoria/3/75(H3N2) infected in MDCK cells expressing wild type M2 after overnight incubation by fluorescence-based miniplaque assay Antiviral activity against Influenza A virus A/Victoria/3/75(H3N2) infected in MDCK cells expressing wild type M2 after overnight incubation by fluorescence-based miniplaque assay	[PMID: 24793875]
MDCK	EC₅₀	208 μM Compound: Amantadine	Antiviral activity against Influenza A virus (A/X-31(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by MTS assay Antiviral activity against Influenza A virus (A/X-31(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by MTS assay	[PMID: 23117173]
MDCK	EC₅₀	212 μM Compound: Amantadine	Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect after 72 hrs by microscopy Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect after 72 hrs by microscopy	[PMID: 24974341]
MDCK	EC₅₀	22.5 μM Compound: 1	Antiviral activity against influenza A virus A/WSN/33-S31N infected in dog MDCK cells after 2 days by naphthalene black dye staining based plaque reduction assay Antiviral activity against influenza A virus A/WSN/33-S31N infected in dog MDCK cells after 2 days by naphthalene black dye staining based plaque reduction assay	[PMID: 23437766]
MDCK	EC₅₀	22.5 μM Compound: 1; AMT	Antiviral activity against Influenza A virus A/WSN/33(H1N1) expressing M2 proton channel S31N mutant infected in MDCK cells assessed as reduction in plaque formation preincubated for 30 mins followed by infection measured on day 2 post infection by naphth Antiviral activity against Influenza A virus A/WSN/33(H1N1) expressing M2 proton channel S31N mutant infected in MDCK cells assessed as reduction in plaque formation preincubated for 30 mins followed by infection measured on day 2 post infection by naphth	[PMID: 26771709]
MDCK	EC₅₀	224 μM Compound: Amantadine	Antiviral activity against Influenza A virus (A/X-31(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by microscopic analysis Antiviral activity against Influenza A virus (A/X-31(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by microscopic analysis	[PMID: 23117173]
MDCK	EC₅₀	224 μM Compound: Amantadine	Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by microscopic analysis Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by microscopic analysis	[PMID: 25752526]
MDCK	EC₅₀	24 μM Compound: 1	Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells expressing M2 V27T/S31N mutant after overnight incubation by fluorescence-based miniplaque assay Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells expressing M2 V27T/S31N mutant after overnight incubation by fluorescence-based miniplaque assay	[PMID: 24793875]
MDCK	EC₅₀	24 μM Compound: 1	Antiviral activity against Influenza A virus A/WS/33(H1N1) infected in MDCK cells expressing M2 S31N mutant after overnight incubation by fluorescence-based miniplaque assay Antiviral activity against Influenza A virus A/WS/33(H1N1) infected in MDCK cells expressing M2 S31N mutant after overnight incubation by fluorescence-based miniplaque assay	[PMID: 24793875]
MDCK	EC₅₀	240 μM Compound: 1	Antiviral activity against Influenza A virus (A/California/07/2009(H1N1)) infected in MDCK cells expressing M2 S31N mutant after overnight incubation by fluorescence-based miniplaque assay Antiviral activity against Influenza A virus (A/California/07/2009(H1N1)) infected in MDCK cells expressing M2 S31N mutant after overnight incubation by fluorescence-based miniplaque assay	[PMID: 24793875]
MDCK	EC₅₀	3.4 μM Compound: amantadine	Antiviral activity against Influenza A virus (A/HK/7/87 (H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis Antiviral activity against Influenza A virus (A/HK/7/87 (H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis	[PMID: 24900429]
MDCK	EC₅₀	3.8 μM Compound: Amantadine	Antiviral activity against Influenza A virus H3N2 A/HK/7/87 infected in MDCK cells assessed as reduction in virus induced cytopathic effect after 4 days by microscopy based method Antiviral activity against Influenza A virus H3N2 A/HK/7/87 infected in MDCK cells assessed as reduction in virus induced cytopathic effect after 4 days by microscopy based method	[PMID: 31753804]
MDCK	EC₅₀	30 μM Compound: amantadine	Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by microscopic analysis Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by microscopic analysis	[PMID: 25899336]
MDCK	EC₅₀	30 μM Compound: Amt	Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) harboring M2 S31N/V27T double mutant channel infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 72 hrs by microscopic analysis Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) harboring M2 S31N/V27T double mutant channel infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 72 hrs by microscopic analysis	[PMID: 24941437]
MDCK	EC₅₀	34 μM Compound: amantadine	Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay	[PMID: 25899336]
MDCK	EC₅₀	34 μM Compound: Amt	Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) harboring M2 channel S31N and V27T mutant infected in MDCK cells assessed as reduction of cytopathic effect after 72 hrs by microsocopic analysis Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) harboring M2 channel S31N and V27T mutant infected in MDCK cells assessed as reduction of cytopathic effect after 72 hrs by microsocopic analysis	[PMID: 24237039]
MDCK	EC₅₀	34 μM Compound: Amt	Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) harboring M2 S31N/V27T double mutant channel infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) harboring M2 S31N/V27T double mutant channel infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay	[PMID: 24941437]
MDCK	EC₅₀	38 μM Compound: Amt	Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) harboring M2 channel S31N and V27T mutant infected in MDCK cells assessed as reduction of cytopathic effect after 72 hrs by MTS assay Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) harboring M2 channel S31N and V27T mutant infected in MDCK cells assessed as reduction of cytopathic effect after 72 hrs by MTS assay	[PMID: 24237039]
MDCK	EC₅₀	4.1 μM Compound: Amantadine	Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by colorimetric formazan-based MTS assay Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by colorimetric formazan-based MTS assay	[PMID: 22459876]
MDCK	EC₅₀	4.28 μM Compound: Amantadine	Antiviral activity against amantadine-resistant influenza A virus JX/312 (H3N2) infected in dog MDCK cells assessed as inhibition of virus induced cytopathic effect after 40 hrs by Cell-Titer-Glo assay Antiviral activity against amantadine-resistant influenza A virus JX/312 (H3N2) infected in dog MDCK cells assessed as inhibition of virus induced cytopathic effect after 40 hrs by Cell-Titer-Glo assay	[PMID: 26686929]
MDCK	EC₅₀	44 μg/mL Compound: Amantadine	Antiviral activity against Influenza A H1N1 virus subtype infected in MDCK cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay Antiviral activity against Influenza A H1N1 virus subtype infected in MDCK cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay	[PMID: 20971531]
MDCK	EC₅₀	44 μM Compound: Amantadine	Antiviral activity against Influenza A virus A/PR/8/34 infected in MDCK cells assessed as reduction of virus induced cytopathic effect measured by visual scoring of cytopathic effect Antiviral activity against Influenza A virus A/PR/8/34 infected in MDCK cells assessed as reduction of virus induced cytopathic effect measured by visual scoring of cytopathic effect	[PMID: 27112451]
MDCK	EC₅₀	453 μM Compound: Amantadine	Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay	[PMID: 25752526]
MDCK	EC₅₀	47 μM Compound: Amantadine	Antiviral activity against Influenza A virus A/PR/8/34 infected in MDCK cells assessed as reduction of virus-induced cytopathic effect measured after 4 days by formazan-based MTS assay Antiviral activity against Influenza A virus A/PR/8/34 infected in MDCK cells assessed as reduction of virus-induced cytopathic effect measured after 4 days by formazan-based MTS assay	[PMID: 27112451]
MDCK	EC₅₀	5 μM Compound: Amantadine	Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as reduction visual scoring of virus-induced cytopathogenicity after 4 days Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as reduction visual scoring of virus-induced cytopathogenicity after 4 days	[PMID: 22459876]
MDCK	EC₅₀	5.1 μM Compound: amantadine	Antiviral activity against amantadine-sensitive Influenza A virus (A/FM/1/47 (H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis Antiviral activity against amantadine-sensitive Influenza A virus (A/FM/1/47 (H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis	[PMID: 24900429]
MDCK	EC₅₀	53 μM Compound: amantadine	Antiviral activity against amantadine-resistant Influenza A virus (A/PR/8/34 (H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis Antiviral activity against amantadine-resistant Influenza A virus (A/PR/8/34 (H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis	[PMID: 24900429]
MDCK	EC₅₀	58 μM Compound: Amantadine	Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by microscopic analysis Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by microscopic analysis	[PMID: 23117173]
MDCK	EC₅₀	61 μM Compound: amantadine	Antiviral activity against Influenza A virus (A/X-31(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis Antiviral activity against Influenza A virus (A/X-31(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis	[PMID: 24900429]
MDCK	EC₅₀	64.2 μM Compound: Amantadine, Symmetrel	Antiviral activity against Influenza virus A/California/07/09 (H1N1)pdm09 infected in MDCK cells assessed as inhibition of viral replication incubated for 1 hr prior to viral infection measured after 48 hrs by hemagglutination reaction Antiviral activity against Influenza virus A/California/07/09 (H1N1)pdm09 infected in MDCK cells assessed as inhibition of viral replication incubated for 1 hr prior to viral infection measured after 48 hrs by hemagglutination reaction	[PMID: 23993669]
MDCK	EC₅₀	65.5 μM Compound: Amantadine	Antiviral activity against Unidentified Influenza A virus (H1N1) infected MDCK cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay Antiviral activity against Unidentified Influenza A virus (H1N1) infected MDCK cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay	[PMID: 32214762]
MDCK	EC₅₀	7.6 μM Compound: Amantadine	Antiviral activity against Influenza A/PR/8/34 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect measured on day 3 post infection by MTS assay Antiviral activity against Influenza A/PR/8/34 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect measured on day 3 post infection by MTS assay	[PMID: 23149298]
MDCK	EC₅₀	75 μM Compound: Amantadine	Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by MTS assay Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by MTS assay	[PMID: 23117173]
MDCK	EC₅₀	75.3 μM Compound: AMN	Antiviral activity against influenza H3N2 virus in MDCK cells assessed as reduction of virus-induced cytopathicity by MTS method Antiviral activity against influenza H3N2 virus in MDCK cells assessed as reduction of virus-induced cytopathicity by MTS method	[PMID: 19281225]
MDCK	EC₅₀	77 μM Compound: amantadine	Antiviral activity against influenza virus A/Puerto Rico/8/34 H1N1 in MDCK cells assessed as effect on virus-induced cytopathogenicity by MTS assay Antiviral activity against influenza virus A/Puerto Rico/8/34 H1N1 in MDCK cells assessed as effect on virus-induced cytopathogenicity by MTS assay	[PMID: 18954995]
MDCK	EC₅₀	87 μg/mL Compound: Amantadin	Antiviral activity against influenza A virus H1N1 infected in MDCK cells assessed as cell viability after 2 days by MTS assay Antiviral activity against influenza A virus H1N1 infected in MDCK cells assessed as cell viability after 2 days by MTS assay	[PMID: 20724039]
MDCK	EC₅₀	89 μM Compound: Amantadine	Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as reduction visual scoring of virus-induced cytopathogenicity after 4 days Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as reduction visual scoring of virus-induced cytopathogenicity after 4 days	[PMID: 22459876]
MDCK	ED₅₀	64.2 μM Compound: Amantadine	Antiviral activity against rimantidine, amantadine-resistant Influenza A virus (A/California/07/09(H1N1)) pdm09 infected in MDCK cells assessed as inhibition of viral replication by hemagglutinin titer assay Antiviral activity against rimantidine, amantadine-resistant Influenza A virus (A/California/07/09(H1N1)) pdm09 infected in MDCK cells assessed as inhibition of viral replication by hemagglutinin titer assay	[PMID: 24631360]
MDCK	IC₅₀	>100 μM Compound: amantadine	Antiviral activity against amantadine-sensitive Influenza A virus A/HK/68 (H3N2) expressing wild type M2 ion channel infected in MDCK cells assessed as protection against virus induced cytopathic effect after 48 hrs by microscopic analysis Antiviral activity against amantadine-sensitive Influenza A virus A/HK/68 (H3N2) expressing wild type M2 ion channel infected in MDCK cells assessed as protection against virus induced cytopathic effect after 48 hrs by microscopic analysis	[PMID: 26722757]
MDCK	IC₅₀	>50 μM Compound: AMD	Antiviral activity against amantidine-resistant Influenza A virus A/WSN/33(H1N1) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effects after 3 days by CCK-8 assay Antiviral activity against amantidine-resistant Influenza A virus A/WSN/33(H1N1) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effects after 3 days by CCK-8 assay	[PMID: 22332894]
MDCK	IC₅₀	0.5 μM Compound: Amantadine	Antiviral activity against wild type M2 ion channel expressing Influenza A virus (A/Hong Kong/1968(H3N2)) infected in MDCK cells preincubated for 30 mins followed by viral infection measured after 72 hrs by CCK-8 assay Antiviral activity against wild type M2 ion channel expressing Influenza A virus (A/Hong Kong/1968(H3N2)) infected in MDCK cells preincubated for 30 mins followed by viral infection measured after 72 hrs by CCK-8 assay	10.1039/C4MD00515E
MDCK	IC₅₀	0.92 μg/mL Compound: Amantadine	Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 3 days by XTT assay Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 3 days by XTT assay	[PMID: 19691312]
MDCK	IC₅₀	10.78 μM Compound: Amantadine	Antiviral activity against Influenza A virus (A/Vietnam/1194/2004(H5N1)) infected in MDCK cells assessed as inhibition of viral replication after 2 to 3 days by crystal violet staining-based plaque reduction assay Antiviral activity against Influenza A virus (A/Vietnam/1194/2004(H5N1)) infected in MDCK cells assessed as inhibition of viral replication after 2 to 3 days by crystal violet staining-based plaque reduction assay	[PMID: 24803363]
MDCK	IC₅₀	13 μM Compound: Amantadine	Antiviral activity against Influenza A virus A/WSN/1933 (H1N1) infected in MDCK cells assessed as protection against virus induced cytopathic effect after 40 hrs by Celltiter-Glo assay Antiviral activity against Influenza A virus A/WSN/1933 (H1N1) infected in MDCK cells assessed as protection against virus induced cytopathic effect after 40 hrs by Celltiter-Glo assay	[PMID: 26686929]
MDCK	IC₅₀	15 μg/mL Compound: amantadine	Antiviral activity against Influenza A virus (A/WSN/33/London (H1N1)) in MDCK cells after 72 hrs by neutral red dye uptake assy Antiviral activity against Influenza A virus (A/WSN/33/London (H1N1)) in MDCK cells after 72 hrs by neutral red dye uptake assy	[PMID: 17602586]
MDCK	IC₅₀	2.22 μM Compound: AMD	Antiviral activity against Influenza A virus A/HK/8/68(H3N2) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effects after 3 days by CCK-8 assay Antiviral activity against Influenza A virus A/HK/8/68(H3N2) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effects after 3 days by CCK-8 assay	[PMID: 22332894]
MDCK	IC₅₀	2.38 μM Compound: 1-Adamantylamine	Antiviral activity against Influenza A virus (A/Vietnam/1194/2004(H5N1)) infected in MDCK cells assessed as inhibition of viral replication by plaque reduction assay Antiviral activity against Influenza A virus (A/Vietnam/1194/2004(H5N1)) infected in MDCK cells assessed as inhibition of viral replication by plaque reduction assay	[PMID: 22226654]
MDCK	IC₅₀	21.11 μM Compound: 1	Antiviral activity against amantadine-sensitive Influenza A virus A/Hong Kong/8/68 (H3N2) infected in MDCK cells assessed as host cell survival after 72 hrs by CCK8 method Antiviral activity against amantadine-sensitive Influenza A virus A/Hong Kong/8/68 (H3N2) infected in MDCK cells assessed as host cell survival after 72 hrs by CCK8 method	[PMID: 21094565]
MDCK	IC₅₀	3.84 μM Compound: 1-Adamantylamine	Antiviral activity against Influenza A virus (A/Vietnam/1194/2004(H5N1)) infected in MDCK cells by plaque reduction assay Antiviral activity against Influenza A virus (A/Vietnam/1194/2004(H5N1)) infected in MDCK cells by plaque reduction assay	[PMID: 23538114]
MDCK	IC₅₀	337.2 μM Compound: amantadine	Antiviral activity against amantadine-resistant Influenza A virus A/WSN/33(H1N1) expressing M2 S31N mutant ion channel infected in MDCK cells assessed as protection against virus induced cytopathic effect after 48 hrs by microscopic analysis Antiviral activity against amantadine-resistant Influenza A virus A/WSN/33(H1N1) expressing M2 S31N mutant ion channel infected in MDCK cells assessed as protection against virus induced cytopathic effect after 48 hrs by microscopic analysis	[PMID: 26722757]
MDCK	IC₅₀	56 μg/mL Compound: Amantadine	Cytotoxicity against MDCK cells by neutral red assay Cytotoxicity against MDCK cells by neutral red assay	[PMID: 9214738]
Oocyte	IC₅₀	16 μM Compound: Amt	Inhibition of Influenza A virus (A/Udorn/72) wild type matrix protein 2 expressed in xenopus oocytes after 2 mins by two-electrode voltage clamp assay Inhibition of Influenza A virus (A/Udorn/72) wild type matrix protein 2 expressed in xenopus oocytes after 2 mins by two-electrode voltage clamp assay	[PMID: 21466220]
Oocyte	IC₅₀	199.9 μM Compound: Amt	Inhibition of Influenza A virus (A/Udorn/72) matrix protein 2 S31N mutant expressed in xenopus oocytes after 2 mins by two-electrode voltage clamp assay Inhibition of Influenza A virus (A/Udorn/72) matrix protein 2 S31N mutant expressed in xenopus oocytes after 2 mins by two-electrode voltage clamp assay	[PMID: 21466220]
Vero	CC₅₀	2019.7 μM Compound: Amantadine	Cytotoxicity against African green monkey Vero cells measured after 48 hrs by crystal violet staining based colorimetric method Cytotoxicity against African green monkey Vero cells measured after 48 hrs by crystal violet staining based colorimetric method	[PMID: 31054861]

体外実験

Amantadine (0-500 μM, 26 h) inhibits SARS-CoV-2 replication, with IC₅₀ concentrations between 83 and 119 μM^[4].
Amantadine (0-100 μg/mL, 24-72 h) markedly inhibits the proliferation of HepG2 and SMMC 7721 cells^[6].
Amantadine (0-75 μg/mL, 48 h) arrests the cell cycle at the G0/G1 phase and induces apoptosis^[6].
Amantadine (0-75 μg/mL, 48 h) reduces the levels of the cell cycle related genes and proteins (cyclin D1, cyclin E and CDK2), reduces Bcl-2 and increases the Bax protein and mRNA levels^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[4]

Cell Line:

Vero E6 cells
Concentration:

500 µM, 100 µM, 20 µM, 4 µM, and 8 nM
Incubation Time:

26 h
Result:

Caused a concentration-dependent reduction (IC₅₀=83 µM) of viral nucleic acids in the supernatant 26 h after infection at 10-500 µM. Caused a concentration-dependent reduction (IC₅₀=119 µM) of viral nucleic acids in the cytosol 26 h after infection.

Cell Proliferation Assay^[6]

Cell Line:

Human HCC cell lines (HepG2 and SMMC-7721) and normal hepatocellular cells (L02 cells)
Concentration:

0, 1, 2, 5, 10, 25, 50 and 100 µg/mL
Incubation Time:

24, 48 and 72 h
Result:

Inhibited cellular proliferation in a time- and dose-dependent manner in HepG2 and SMMC-7721 cells.

Cell Cycle Analysis^[6]

Cell Line:

HepG2 and SMMC-7721 cells
Concentration:

0, 10, 25, 50 and 75 µg/mL
Incubation Time:

48 h
Result:

Significantly increased the population of HepG2 and SMMC-7721 cells in the G0/G1 phase in a dose-dependent manner, and significantly decreased the number of HepG2 cells in the S phase.

Apoptosis Analysis^[6]

Cell Line:

HepG2 and SMMC-7721 cells
Concentration:

0, 10, 25, 50 and 75 µg/mL
Incubation Time:

48 h
Result:

Markedly increased the percentage of apoptotic HepG2 and SMMC-7721 cells (early- and late-stage apoptosis) in a dose-dependent manner.

Western Blot Analysis^[6]

Cell Line:

HepG2 and SMMC-7721 cells
Concentration:

0, 10, 25, 50 and 75 µg/mL
Incubation Time:

48 h
Result:

Showed downregulation of cyclin D1, cyclin E and CDK2, and showed a decrease in Bcl-2 levels and an increase of Bax levels in HepG2 and SMMC-7721 cells.

RT-PCR^[6]

Cell Line:

HepG2 and SMMC-7721 cells
Concentration:

0, 10, 25, 50 and 75 µg/mL
Incubation Time:

48 h
Result:

Revealed an increase in Bax and decrease in Bcl-2 genes.

体内実験

Amantadine (25 mg/kg, IP, once daily for 3 days) inhibits surgery induced neuroinflammation and learning and memory impairment^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Fischer 344 rats (Four-month old, male, 290-330 g, 15 rats each group)^[5]
Dosage:

25 mg/kg
Administration:

IP, once daily for 3 days (the first dose at 15 min before surgery)
Result:

Inhibited surgery induced neuroinflammation and learning and memory impairment, increased GDNF (glial cell line-derived neurotrophic factor) that was co-localized with glial fibrillary acidic protein (an astrocytic marker) in the hippocampus.

化学情報

CAS 番号 768-94-5
性状 Solid
分子量 151.25
分子式 C₁₀H₁₇N
Color White to off-white
SMILES

NC12C[C@H]3C[C@@H](C2)C[C@@H](C1)C3
別名

1-Adamantanamine; 1-Aminoadamantane; 1-アダマンタナミン
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (11)

All

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development. [Abstract]

2021 Mar 27;6(1):134. PMID: 33774649
Emerg Microbes Infect

Efficient airborne transmission of influenza D virus in ferret models and serological evidence of human exposure in Northeast China. [Abstract]

2025 Dec;14(1):2564308. PMID: 41069204
Int J Nanomedicine

The Optimization Design Of Lactoferrin Loaded HupA Nanoemulsion For Targeted Drug Transport Via Intranasal Route. [Abstract]

2019 Nov 27;14:9217-9234. PMID: 31819426
PLoS Pathog

Anti-orthopoxvirus drugs inhibit lumpy skin disease virus replication by targeting viral DNA polymerase. [Abstract]

2026 Jan 26;22(1):e1013903. PMID: 41587213
Int J Mol Sci

Lycorine Inhibits Influenza Virus Replication by Affecting Nascent Nucleoporin Nup93 Synthesis. [Abstract]

2025 Jun 3;26(11):5358. PMID: 40508167
Virol J

Bisbenzylisoquinoline alkaloids inhibit influenza virus replication by disrupting endosomal acidification. [Abstract]

2025 Jun 4;22(1):181. PMID: 40468427
Open Forum Infect Dis

Toward Personalized Medicine: The Effect of Treatment of Chronic Enterovirus Diarrhea in an Immunocompromised Patient and the Correlation With In Vitro Models. [Abstract]

2025 Apr 10;12(5):ofaf212. PMID: 40302715
ACS Infect Dis

Development of a Universal Type A Influenza Viral RdRp-Induced Reporter System with Potential for Antiviral Drug Screening. [Abstract]

2025 Jun 13;11(6):1437-1447. PMID: 40421776
Chem Phys Lipids

Amantadine interactions with phase separated lipid membranes. [Abstract]

2024 May 11:262:105397. PMID: 38740276
Vet Microbiol

The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]

2026 May:316:110992. PMID: 41865607
bioRxiv

2026 Jun 10.

溶剤 & 溶解度

体外:

DMSO : 6.48 mg/mL (42.84 mM; ultrasonic and warming and adjust pH to 4 with 1 M HCl and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

6.6116 mL

33.0578 mL

66.1157 mL

5 mM

1.3223 mL

6.6116 mL

13.2231 mL

10 mM

0.6612 mL

3.3058 mL

6.6116 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass

濃度

体積

分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始)

体積 _(開始)

濃度 _(終了)

体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 1 mg/mL (6.61 mM); Clear solution

This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 1 mg/mL (6.61 mM); Clear solution

This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 0.5 mg/mL (3.31 mM); Clear solution

This protocol yields a clear solution of ≥ 0.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (5.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage
mg/kg
Animal Weight (Per Animal)
g
Dosing Volume (Per Animal)
μL
Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (283 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Suzuki H, et al. Emergence of amantadine-resistant influenza A viruses: epidemiological study. J Infect Chemother. 2003;9(3):195-200. [Content Brief]

[2]. Hubsher G, et al. Amantadine: the journey from fighting flu to treating Parkinson disease. Neurology. 2012;78(14):1096-1099. [Content Brief]

[3]. Donald F Smee, et al. A review of compounds exhibiting anti-orthopoxvirus activity in animal models. Antiviral Res. 2003 Jan;57(1-2):41-52. [Content Brief]

[4]. Fink K, et al. Amantadine Inhibits SARS-CoV-2 In Vitro. Viruses. 2021 Mar 24;13(4):539. [Content Brief]

[5]. Zhang J, et al. Amantadine alleviates postoperative cognitive dysfunction possibly by increasing glial cell line-derived neurotrophic factor in rats. Anesthesiology. 2014 Oct;121(4):773-85. [Content Brief]

[6]. Lan Z, et al. Amantadine inhibits cellular proliferation and induces the apoptosis of hepatocellular cancer cells in vitro. Int J Mol Med. 2015;36(3):904-910. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	6.6116 mL	33.0579 mL	66.1157 mL	165.2893 mL
	5 mM	1.3223 mL	6.6116 mL	13.2231 mL	33.0579 mL
	10 mM	0.6612 mL	3.3058 mL	6.6116 mL	16.5289 mL
	15 mM	0.4408 mL	2.2039 mL	4.4077 mL	11.0193 mL
	20 mM	0.3306 mL	1.6529 mL	3.3058 mL	8.2645 mL
	25 mM	0.2645 mL	1.3223 mL	2.6446 mL	6.6116 mL
	30 mM	0.2204 mL	1.1019 mL	2.2039 mL	5.5096 mL
	40 mM	0.1653 mL	0.8264 mL	1.6529 mL	4.1322 mL

Amantadine

11 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Amantadine

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

Structurally Diverse Fragment Library

3D Diverse Fragment Library

Drug Fragment Library

MedChemExpress（MCE）の使用を引用している文献 Amantadine

CDK アイソフォーム固有の製品をすべて表示

Bcl-2 Family アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (11)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Amantadine

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

Structurally Diverse Fragment Library

3D Diverse Fragment Library

Drug Fragment Library

MedChemExpress（MCE）の使用を引用している文献 Amantadine

CDK アイソフォーム固有の製品をすべて表示

Bcl-2 Family アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (11)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Amantadine 関連分類

製品番号: HY-B0402